UnknownNot applicableNCT04619199
Influence of Socioeconomic and Environmental Factors on the Natural History of Idiopathic Pulmonary Fibrosis
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Principal Investigator
- Lucile SESE, DrAssistance Publique - Hôpitaux de Paris
- Intervention
- Blood sample(diagnostic_test)
- Enrollment
- 200 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (16)
- 001 - Service Pneumologie, Bobigny, Avicenne, France
- 002 - Service Explorations Fonctionnelles Respiratoires, Bobigny, Avicenne, France
- 003 - Service Pneumologie, Paris, Bichat, France
- 016 - Service Pneumologie, Caen, CHU Caen Normandie, France
- 010 - Service Pneumologie, Dijon, CHU Dijon, France
- 013 - Service Pneumologie, Grenoble, CHU Grenoble, France
- 008 - Service Pneumologie, Lille, CHU Lille, France
- 015 - Service Pneumologie, Montpellier, CHU Montpellier, France
- 007 - Service Pneumologie, Rennes, CHU Pontchaillou, France
- 011 - Service Pneumologie, Strasbourg, CHU Strasbourg, France
- 012 - Service Pneumologie, Tours, CHU Tours, France
- 014 - Service Pneumologie, Meaux, GHEF, France
- 005 - Service Pneumologie, Paris, HEGP, France
- 006 - Service Pneumologie, Lyon, Hospices Civils de Lyon, France
- 004 - Service de Pneumologie, Paris, Tenon, France
- +1 more locations on ClinicalTrials.gov
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04619199 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou
- RECRUITINGPHASE3NCT07299695Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisArgyrios Tzouvelekis
- RECRUITINGPHASE2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics